Thymic carcinoma

This phase II trial is testing a drug called ivonescimab in 25 people with thymic carcinoma, a rare cancer of the thymus gland that has already been treated. Ivonescimab is an immunotherapy that helps the body's immune system recognize and attack cancer cells. The main goal is to…

This study tests a drug called sacituzumab govitecan in adults with advanced thymoma or thymic carcinoma that has worsened after at least one prior treatment. The main goal is to see how many patients' tumors shrink or disappear. Participants receive the drug intravenously weekly…

This study tests a drug called PT-112 in people with thymoma or thymic cancer that has come back or worsened after standard treatment. PT-112 is designed to kill cancer cells and boost the immune system. About 53 adults will receive the drug intravenously in 28-day cycles. The ma…

This phase 2 trial tests a drug called sacituzumab tirumotecan (Sac-TMT) in 30 people with advanced thymic carcinoma that has worsened after platinum-based chemotherapy. Participants receive the drug every two weeks, and doctors will check how well it shrinks tumors and monitor s…

This early-phase trial is testing the safety of the immunotherapy drug pembrolizumab (Keytruda) in 37 people with thymoma or thymic carcinoma that cannot be removed by surgery. The drug helps the immune system attack cancer cells. Researchers are looking at side effects and how w…

This study tests a shorter, higher-dose-per-day radiation schedule (hypofractionated radiotherapy) given after complete surgical removal of stage II or III thymic epithelial tumors. The goal is to see if this approach is safe and tolerable, while also checking how well it control…

This study tests whether specially engineered immune cells (CAR-NK cells) can safely treat people with advanced thymus cancers that have not responded to other treatments. Participants will receive cells that target one of three proteins found on their tumor. The goal is to find …

This study tests whether combining the drug envolizumab with radiation therapy before surgery can safely shrink tumors in people with locally advanced thymic carcinoma. About 25 adults aged 18-75 with stage III-IVA disease who have not had prior treatment will receive the combina…

This phase 3 trial tests whether adding chemotherapy to standard radiation after thymic cancer surgery can prevent the cancer from coming back. About 172 adults who had complete tumor removal will receive either radiation alone or radiation plus four cycles of chemotherapy (pacli…

This study looks at whether giving radiation therapy after surgery can stop thymoma (a rare chest tumor) from returning in patients with stage II or III disease. About 314 adults aged 18-75 who had the tumor completely removed will be randomly assigned to receive radiation or jus…

This phase 2 trial is testing a combination of two drugs—tislelizumab (an immunotherapy) and anlotinib (a targeted therapy)—as a second-line treatment for people with thymoma or thymic carcinoma whose cancer has progressed after initial chemotherapy. The study will enroll 20 part…

This study tests whether a newer, MRI-guided radiation method (MRgART) is gentler on the heart than standard radiation (LINAC) for people with lung, esophageal, or other chest cancers. About 60 adults will receive radiation and have their heart function checked via MRI and blood …

This study aims to collect tumor, normal tissue, and blood samples from up to 1559 people with cancers of the lung, esophagus, or pleura. Researchers will analyze genetic and epigenetic changes to better understand these diseases and identify potential markers for future treatmen…

This study aims to collect blood, urine, tumor samples, and health data from up to 1,000 people with malignant mesothelioma or other cancers that express a protein called mesothelin. Participants will be followed over time to track the course of their disease. The goal is to buil…